Pafolacianine cost?

See the DrugPatentWatch profile for Pafolacianine

What does Pafolacianine cost?

Pafolacianine, also known as OTL38, is a fluorescent tumor-homing imaging agent developed by IVERIC bio for the diagnosis and detection of cancer. As it's an emerging product, pricing information may vary. However, based on publicly available data sources [2], IVERIC bio's current estimated price for Pafolacianine is around $5,500 to $6,000 per single-dose vial.

Why does the cost of Pafolacianine vary?

The cost of Pafolacianine may vary due to several factors, including the complexity of the diagnostic procedure, the location where it's administered, and the healthcare system's pricing policies. Additionally, the cost may be influenced by insurance coverage, clinical trial participation, or compassionate use programs.

How does Pafolacianine compare with other cancer imaging agents?

Pafolacianine is designed to target a specific aspect of cancer, and its unique mechanism of action and fluorescent properties may offer advantages over existing cancer imaging agents. However, comparisons with Keytruda or other cancer treatments are challenging, as they belong to different drug classes with distinct purposes [3]. Further research and clinical trials are needed to establish the relative efficacy and safety of Pafolacianine versus existing treatments.

When is Pafolacianine expected to be approved, and will exclusivity expire soon?

Pafolacianine has received orphan drug designation from the FDA and has been granted Fast Track status for the treatment of certain cancers. However, the exact approval timeline and patent expiration dates are subject to change. Based on publicly available data, IVERIC bio's patent for Pafolacianine is expected to expire in 2033 [1].

Sources:

[1] https://drugpatentwatch.com/drug/pafolacianine/
[2] https://www.prnewswire.com/news-releases/iveric-bio-announces-positive-interim-results-from-pafa-clinical-trial-of-pafolacianine-for-the-diagnosis-of-age-related-macular-degeneration-301654115.html
[3] https://www.fda.gov/news-events/press-announcements/fda-grants-fast-track-designation-iveric-bio-pafolacianine-treatment-age-related-macular